## Becca Asquith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5225066/publications.pdf

Version: 2024-02-01

87723 114278 4,469 78 38 citations h-index g-index papers

82 82 82 5795 docs citations times ranked citing authors all docs

63

#	Article	IF	CITATIONS
1	The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. Journal of Experimental Medicine, 2017, 214, 1913-1923.	4.2	725
2	In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology, 2007, 121, 258-265.	2.0	257
3	Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood, 2016, 127, 3431-3438.	0.6	199
4	Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140291.	1.8	156
5	B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood, 2005, 105, 3633-3640.	0.6	155
6	Inefficient Cytotoxic T Lymphocyte–Mediated Killing of HIV-1–Infected Cells In Vivo. PLoS Biology, 2006, 4, e90.	2.6	147
7	HLA Class I Binding of HBZ Determines Outcome in HTLV-1 Infection. PLoS Pathogens, 2010, 6, e1001117.	2.1	127
8	Measurement and modeling of human T cell kinetics. European Journal of Immunology, 2003, 33, 2316-2326.	1.6	114
9	Lymphocyte kinetics: the interpretation of labelling data. Trends in Immunology, 2002, 23, 596-601.	2.9	106
10	Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood, 2013, 122, 2205-2212.	0.6	106
11	In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8035-8040.	3.3	105
12	HTLV-1: Persistence and pathogenesis. Virology, 2013, 435, 131-140.	1.1	91
13	Human T Cell Lymphotropic Virus (HTLV) Type–1–Specific CD8+T Cells: Frequency and Immunodominance Hierarchy. Journal of Infectious Diseases, 2004, 189, 2294-2298.	1.9	79
14	The Role of CTLs in Persistent Viral Infection: Cytolytic Gene Expression in CD8+ Lymphocytes Distinguishes between Individuals with a High or Low Proviral Load of Human T Cell Lymphotropic Virus Type 1. Journal of Immunology, 2004, 173, 5121-5129.	0.4	77
15	A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. Journal of General Virology, 2005, 86, 1515-1523.	1.3	76
16	Quantification of HTLV-1 Clonality and TCR Diversity. PLoS Computational Biology, 2014, 10, e1003646.	1.5	71
17	Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients. Blood, 2007, 110, 3722-3728.	0.6	70
18	Human Stem Cell-like Memory T Cells Are Maintained in a State of Dynamic Flux. Cell Reports, 2016, 17, 2811-2818.	2.9	67

#	Article	IF	Citations
19	KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection. PLoS Pathogens, 2011, 7, e1002270.	2.1	67
20	In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6365-6370.	3.3	64
21	In vivo Expression of Human T-lymphotropic Virus Type 1 Basic Leucine-Zipper Protein Generates Specific CD8+ and CD4+ T-Lymphocyte Responses that Correlate with Clinical Outcome. Journal of Infectious Diseases, 2011, 203, 529-536.	1.9	64
22	Quantifying HTLV″ dynamics. Immunology and Cell Biology, 2007, 85, 280-286.	1.0	60
23	The Avidity and Lytic Efficiency of the CTL Response to HTLV-1. Journal of Immunology, 2009, 182, 5723-5729.	0.4	60
24	Quantifying lymphocyte kinetics in vivo using carboxyfluorescein diacetate succinimidyl ester. Proceedings of the Royal Society B: Biological Sciences, 2006, 273, 1165-1171.	1.2	58
25	Cell dynamics and immune response to BLV infection: a unifying model. Frontiers in Bioscience - Landmark, 2007, 12, 1520.	3.0	57
26	Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology, 2005, 2, 75.	0.9	55
27	High Circulating Frequencies of Tumor Necrosis Factor Alpha- and Interleukin-2-Secreting Human T-Lymphotropic Virus Type 1 (HTLV-1)-Specific CD4 + T Cells in Patients with HTLV-1-Associated Neurological Disease. Journal of Virology, 2003, 77, 9716-9722.	1.5	52
28	How does HTLV-I persist despite a strong cell-mediated immune response?. Trends in Immunology, 2008, 29, 4-11.	2.9	52
29	Strongyloidiasis and Infective Dermatitis Alter Human T Lymphotropic Virus-1 Clonality in vivo. PLoS Pathogens, 2013, 9, e1003263.	2.1	51
30	Human T Cell Memory: A Dynamic View. Vaccines, 2017, 5, 5.	2.1	50
31	Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10048-10053.	3.3	47
32	Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness. PLoS Biology, 2018, 16, e2005523.	2.6	46
33	Is human T–cell lymphotropic virus type I really silent?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1013-1019.	1.8	44
34	The immune control of HTLV-1 infection: selection forces and dynamics. Frontiers in Bioscience - Landmark, 2009, Volume, 2889.	3.0	43
35	Inhibitory killer cell immunoglobulin-like receptors strengthen CD8 <sup>+</sup> T cell–mediated control of HIV-1, HCV, and HTLV-1. Science Immunology, 2018, 3, .	5.6	43
36	Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood, 2011, 118, 6306-6309.	0.6	42

#	Article	IF	Citations
37	Rapid turnover of T cells in acute infectious mononucleosis. European Journal of Immunology, 2003, 33, 2655-2665.	1.6	41
38	Reduction of B cell turnover in chronic lymphocytic leukaemia. British Journal of Haematology, 2008, 143, 240-247.	1.2	39
39	Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose. Nature Protocols, 2009, 4, 1313-1327.	5.5	39
40	Rates of CTL Killing in Persistent Viral Infection In Vivo. PLoS Computational Biology, 2014, 10, e1003534.	1.5	34
41	Lymphocyte kinetics in health and disease. Trends in Immunology, 2009, 30, 182-189.	2.9	33
42	Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa. Journal of Immunology, 2018, 200, 2640-2655.	0.4	32
43	Reduced Cell Turnover in Bovine LeukemiaVirus-Infected, Persistently LymphocytoticCattle. Journal of Virology, 2003, 77, 13073-13083.	1.5	31
44	The dynamics of T-cell fratricide: application of a robust approach to mathematical modelling in immunology. Journal of Theoretical Biology, 2003, 222, 53-69.	0.8	30
45	Review. An introduction to lymphocyte and viral dynamics: the power and limitations of mathematical analysis. Proceedings of the Royal Society B: Biological Sciences, 2003, 270, 1651-1657.	1.2	30
46	Why Don't CD8+ T Cells Reduce the Lifespan of SIV-Infected Cells In Vivo?. PLoS Computational Biology, 2011, 7, e1002200.	1.5	30
47	The Role of Cytotoxic T Lymphocytes in Human T-cell Lymphotropic Virus Type 1 Infection. Journal of Theoretical Biology, 2000, 207, 65-79.	0.8	29
48	Can Non-lytic CD8+ T Cells Drive HIV-1 Escape?. PLoS Pathogens, 2013, 9, e1003656.	2.1	29
49	T-Cell Epitope Prediction: Rescaling Can Mask Biological Variation between MHC Molecules. PLoS Computational Biology, 2009, 5, e1000327.	1.5	27
50	Quantification of the Relative Importance of CTL, B Cell, NK Cell, and Target Cell Limitation in the Control of Primary SIV-Infection. PLoS Computational Biology, 2011, 7, e1001103.	1.5	23
51	Viral Expression Directs the Fate of B Cells in Bovine Leukemia Virus-Infected Sheep. Journal of Virology, 2012, 86, 621-624.	1.5	23
52	Current estimates of T cell kinetics in humans. Current Opinion in Systems Biology, 2019, 18, 77-86.	1.3	23
53	Peripheral Blood B-Cell Death Compensates for Excessive Proliferation in Lymphoid Tissues and Maintains Homeostasis in Bovine Leukemia Virus-InfectedSheep. Journal of Virology, 2006, 80, 9710-9719.	1.5	22
54	The relative contributions of infectious and mitotic spread to HTLV-1 persistence. PLoS Computational Biology, 2020, 16, e1007470.	1.5	22

#	Article	IF	CITATIONS
55	The Efficiency of the Human CD8+ T Cell Response: How Should We Quantify It, What Determines It, and Does It Matter?. PLoS Computational Biology, 2012, 8, e1002381.	1.5	20
56	Quantifying the Impact of Human Immunodeficiency Virus-1 Escape From Cytotoxic T-Lymphocytes. PLoS Computational Biology, 2010, 6, e1000981.	1.5	19
57	CD57+ Memory T Cells Proliferate InÂVivo. Cell Reports, 2020, 33, 108501.	2.9	18
58	Reconciling Estimates of Cell Proliferation from Stable Isotope Labeling Experiments. PLoS Computational Biology, 2015, 11, e1004355.	1.5	17
59	Identifying the immune interactions underlying HLA class I disease associations. ELife, 2020, 9, .	2.8	17
60	Spleen-Dependent Turnover of CD11b Peripheral Blood B Lymphocytes in Bovine Leukemia Virus-Infected Sheep. Journal of Virology, 2006, 80, 11998-12008.	1.5	16
61	HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP. Virology Journal, 2014, 11, 172.	1.4	16
62	Cell-Mediated Immune Response to Human T-Lymphotropic Virus Type I. Viral Immunology, 2005, 18, 293-305.	0.6	15
63	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	1.2	14
64	Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans. Frontiers in Immunology, 2017, 8, 474.	2.2	13
65	The Evolutionary Selective Advantage of HIV-1 Escape Variants and the Contribution of Escape to the HLA-Associated Risk of AIDS Progression. PLoS ONE, 2008, 3, e3486.	1.1	13
66	Earlier Onset of Î'-Retrovirus-Induced Leukemia after Splenectomy. PLoS ONE, 2009, 4, e6943.	1.1	12
67	HIV-1 adaptation to NK cell-mediated immune pressure. PLoS Pathogens, 2017, 13, e1006361.	2.1	11
68	Non-commutative geometry and the strong force. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics, 1996, 366, 220-223.	1.5	9
69	Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1. Oncogene, 2005, 24, 7514-7523.	2.6	9
70	In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection. Human Immunology, 2012, 73, 783-787.	1.2	8
71	How lymphocytes add up. Nature Immunology, 2017, 18, 12-13.	7.0	6
72	The Rules of Human T Cell Fate in vivo. Frontiers in Immunology, 2020, 11, 573.	2.2	5

#	Article	IF	CITATIONS
73	Short Communication An Interferon-γELISPOT Assay with Two Cytotoxic T Cell Epitopes Derived from HTLV-1 Tax Region 161-233 Discriminates HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Patients from Asymptomatic HTLV-1 Carriers in a Peruvian Population. AIDS Research and Human Retroviruses, 2011, 27, 1207-1212.	0.5	4
74	BIITE: A Tool to Determine HLA Class II Epitopes from T Cell ELISpot Data. PLoS Computational Biology, 2016, 12, e1004796.	1.5	4
75	Modelling Lymphocyte Dynamics In Vivo. , 2011, , 141-169.		2
76	Clonality, latency and integration of HTLV-1 in vivo. Retrovirology, 2013, 10, .	0.9	0
77	Estimating rates of de novo infection and mitotic replication in HTLV-1 persistence: de novo infection continues after early infection. Retrovirology, 2015, 12, .	0.9	O
78	Reduced Rates of B Cell Proliferation in Chronic Lymphocytic Leukemia Blood, 2006, 108, 2821-2821.	0.6	0